Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases.
MAbs. 2016;8(1):141-9. doi: 10.1080/19420862.2015.1093266. Epub 2015 Sep 22.
MAbs. 2016.
PMID: 26390837
Free PMC article.
Clinical Trial.
A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action.
Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, Grabulovski D.
Brack S, et al. Among authors: von der bey u.
Mol Cancer Ther. 2014 Aug;13(8):2030-9. doi: 10.1158/1535-7163.MCT-14-0046-T. Epub 2014 Jul 3.
Mol Cancer Ther. 2014.
PMID: 24994770
Item in Clipboard
COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
Klupsch K, Baeriswyl V, Scholz R, Dannenberg J, Santimaria R, Senn D, Kage E, Zumsteg A, Attinger-Toller I, von der Bey U, König-Friedrich S, Dupuy F, Lembke W, Albani C, Wendelspiess S, Dinkel L, Saro D, Hepler RW, Laszlo GS, Gudgeon CJ, Bertschinger J, Brack S, Walter RB.
Klupsch K, et al. Among authors: von der bey u.
Leukemia. 2019 Mar;33(3):805-808. doi: 10.1038/s41375-018-0249-z. Epub 2018 Sep 11.
Leukemia. 2019.
PMID: 30206306
No abstract available.
Item in Clipboard
Cite
Cite